{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:43:37Z","timestamp":1793090617729,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":554,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.exphem.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T21:06:39Z","timestamp":1644440799000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-5326","authenticated-orcid":false,"given":"Ismail","family":"Can","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2984-0834","authenticated-orcid":false,"given":"Michelle J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Sakemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.02.001_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"key":"10.1016\/j.exphem.2022.02.001_bib0003","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0004","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2022.02.001_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0007","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0008","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","article-title":"CAR-T cells and combination therapies: what's next in the immunotherapy revolution?","volume":"129","author":"Ramello","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0011","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T Cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2021.1894648","article-title":"Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies","volume":"62","author":"Sakemura","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2022.02.001_bib0014","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0016","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0017","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2022.02.001_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0019","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.exphem.2022.02.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0021","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/890178","article-title":"Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects","volume":"2012","author":"Ding","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0023","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","article-title":"Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis","volume":"74","author":"Ding","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0676-3","article-title":"Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia","volume":"11","author":"Zou","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.02.001_bib0026","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.exphem.2022.02.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0028","unstructured":"Hackethal V. In remission for 10 years: long-term toxicity data on CAR T cells. July 21, 2020. Available at: https:\/\/www.medscape.com\/viewarticle\/934286. Accessed January 20, 2022."},{"issue":"7","key":"10.1016\/j.exphem.2022.02.001_bib0029","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3324\/haematol.2009.009274","article-title":"Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug","volume":"94","author":"Ramsay","year":"2009","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2022.02.001_bib0031","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2022.02.001_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140491","article-title":"Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients","volume":"136","author":"Siddiqi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0033","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.02.001_bib0034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8\u00a0+\u00a0T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2022.02.001_bib0035","doi-asserted-by":"crossref","first-page":"14336","DOI":"10.1073\/pnas.1221740110","article-title":"CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability","volume":"110","author":"Van Der Windt","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2022.02.001_bib0036","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0037","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Geltink","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.02.001_bib0039","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.it.2012.01.010","article-title":"Metabolic pathways in T cell fate and function","volume":"33","author":"Gerriets","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","article-title":"The CD28 signaling pathway regulates glucose metabolism","volume":"16","author":"Frauwirth","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2022.02.001_bib0041","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"Van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2022.02.001_bib0042","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2019-123277","article-title":"Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma","volume":"134","author":"Sakemura","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","article-title":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy","volume":"27","author":"Sterner","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0044","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2013derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0046","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/leu.2016.217","article-title":"Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression","volume":"31","author":"Boysen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.02.001_bib0047","doi-asserted-by":"crossref","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2022.02.001_bib0048","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.02.001_bib0049","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0051","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.exphem.2022.02.001_bib0052","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0053","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"M\u00fcller","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2022.02.001_bib0054","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.02.001_bib0056","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0057","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0058","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","article-title":"Human \u03b3\u03b4 T cells as mediators of chimaeric-receptor redirected anti-tumour immunity","volume":"126","author":"Rischer","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0059","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2022.02.001_bib0060","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12885-017-3539-3","article-title":"RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: a safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma","volume":"17","author":"Harrer","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2022.02.001_bib0061","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0062","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Philip","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0063","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.02.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4280.4280","article-title":"Multiplex Cripsr\/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia","volume":"126","author":"Ren","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0066","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2022.02.001_bib0067","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.02.001_bib0068","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2022.02.001_bib0069","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0070","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0071","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0072","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.02.001_bib0073","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.02.001_bib0074","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.02.001_bib0075","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.02.001_bib0076","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0077","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2022.02.001_bib0078","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.02.001_bib0079","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.02.001_bib0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2022.02.001_bib0081","article-title":"A dominant negative SHP-2 which abrogates PD-1 signalling pathways and restores function of cytotoxic CAR T cells","volume":"130","author":"Baldan","year":"2017","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:36:53Z","timestamp":1759567013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":81,"alternative-id":["S0301472X22000698"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.02.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}